On September 17, 2024, Fady Malik, Executive Vice President of Research & Development at Cytokinetics Inc (CYTK, Financial), sold 7,300 shares of the company. The transaction was documented in a recent SEC Filing. Following this sale, the insider now owns 120,920 shares of Cytokinetics Inc.
Cytokinetics Inc is a biopharmaceutical company focused on the discovery and development of next-generation therapeutics for diseases characterized by impaired muscle function. The company is dedicated to enhancing the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Over the past year, the insider has sold a total of 160,407 shares and has not made any purchases. This recent transaction is part of a broader trend observed over the past year at Cytokinetics Inc, where there have been 48 insider sells and no insider buys.
On the day of the sale, shares of Cytokinetics Inc were trading at $56.77. This pricing gives the company a market cap of approximately $6.61 billion. According to the GF Value, an intrinsic value estimate calculated by GuruFocus, the stock is currently significantly overvalued with a price-to-GF-Value ratio of 24.79.
The GF Value is determined by historical trading multiples such as the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on the company’s past returns and growth, and future business performance estimates from Morningstar analysts.
This insider sale may interest investors tracking insider behaviors as an indicator of confidence levels regarding the company's current valuation and future prospects.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
